FDA Prescription Drug User Fee Rates: Fiscal Year 2017

August 2, 2016

The Prescription Drug User Fee Amendments of 2012 (PDUFA V) allows FDA to collect user fees for the review of applications concerning human drug and biological products, the establishments where these products are made, and on the products themselves.  Each year these rates are adjusted in order to meet the needs of the Agency and to account for inflation.  As such, last week the FDA released its rates for fiscal year 2017, which are as follows:

Fee Category:

FY 20147 Rates:

Application Requiring Clinical Data

$2,038,100

Application not Requiring Clinical Data

$1,019,050

Establishment

$512,200

Product

$97,750

 

FDA has decreased these fees, as compared to its 2016 rates.  The new rates take effect on October 1, 2016, and will remain constant until September 30, 2017, when the FDA's FY 2018 rates will take effect.

Are you developing an FDA-regulated product? We can help you get your product approved by the FDA in less time and for less money. To learn more about our unique approach that combines scientific knowledge with regulatory expertise and how that has helped our clients achieve a successful outcome with FDA, contact us today.



Agency Alerts General Regulatory

August 3, 2016

FDA Biosimilar User Fee Rates: Fiscal Year 2017

The Biosimilar User Fee Act of 2012 (BsUFA) authorizes the FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development (BPD).  These user...

Read the Full Article
Agency Alerts

August 7, 2015

FDA Prescription Drug User Fee Rates: Fiscal Year 2016

As amended by the Prescription Drug User Fee Amendments of 2012, The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to assess and collect fees from sponsors submitting applications...

Read the Full Article
Agency Alerts General Regulatory

September 17, 2015

FDA To Increase Tropical Disease Priority Review User Fee Rate In 2016

Starting October 1, 2015, the FDA tropical disease priority review user fee rate is set to increase to $2,727,000, up nearly $200,000 from 2015’s rate of $2,562,000. Under the Prescription Drug User...

Read the Full Article